Younger population seeing high rates of infection amid Covid surge: Experts

As India confronts a fresh surge in Covid-19 cases, doctors suggest that the virus is disproportionately affecting younger age groups, with the 18-45 age bracket bearing the brunt of the infection.
According to data available on the Union health ministry's Covid dashboard, India has 5,976 active cases from 29 states and Union Territories (UTs) as of June 19. Of these, Kerala has the highest caseload at 1,309, followed by Gujarat and Delhi at 1,046 and 632 cases, respectively.
While the government does not give an age- or gender-wise breakup of cases, doctors are seeing a noticeable increase in Covid-19 cases among young adults, specifically those aged between 18 and 45.
Tushar Tayal, consultant-internal medicine at CK Birla Hospital, Gurugram, said that on average, 10-12 patients per day were coming to him with flu-like symptoms and a small but steady percentage of them were testing positive for Covid-19.
'This may be indicative of a silent surge that is frequently overlooked because other viral infections overlap and (there's) an overall reduction in the rate of testing,' he added.
Aakashneel Bhattacharya, consultant-infectious diseases at Paras Heath in Gurugram said that 80-85 per cent of Covid patients coming to him fell into the same 18-45 age bracket.
Young adults previously considered to be at relatively low risk of severe illness are now showing heightened susceptibility, particularly those with a poor follow-up history of vaccination or waning immunity.
Divya K S, an infectious disease specialist at Apollo Hospitals in Sheshadripuram, Bengaluru, said that waning immunity over the years, in addition to the emergence of immune-evading strains, made the younger population more vulnerable.
Tayal said that in the 18-25 age group, most came with high-grade fever, throat pain, tiredness, body pain, and sometimes gastrointestinal symptoms of nausea or diarrhoea. Some also complained of a dry cough lasting for days and mild difficulty in breathing.
In individuals over 30, symptoms persisted longer, and there were more instances of prolonged fatigue or post-viral cough, he added.
Commenting on the reasons, Bhattacharya said younger people were at high risk of contracting the infection as they were the ones who mostly went out and mixed up with other people in the community.
'Till now, we are not seeing patients developing serious pneumonia or having low oxygen saturation. While a few patients may have had minor pneumonia, they are not requiring oxygen,' he added.
Tayal, however, said that although most cases of Covid in younger patients were not serious, there should be caution against complacency. 'Reinfections are being observed even in persons who have been vaccinated or infected before, pointing to changing viral strains,' he added.
Another reason was that many younger patients were delaying getting tested, assuming the infection to be a seasonal flu or viral fever, he further said.
Nidhin Mohan, consultant-internal medicine, Narayana Health City, Bengaluru, said that there was a spike among individuals who had recently travelled, especially for work or weddings, without taking adequate precautions.
'Infectious strains that spread faster within a group that is in close contact with each other can result in more case numbers among younger populations, who tend to be at the centre of workplace and social interactions,' said Deepesh G Aggarwal, consultant physician and head of department for critical care medicine at Saifee Hospital, Mumbai.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Time of India

2 hours ago

• Time of India

A shot of hope

New HIV medicine is powerful – but can everyone afford it? A new medicine called lenacapavir has just been approved in the US to help stop people from getting HIV, the virus that causes AIDS. That's big news! Even though fewer people are getting HIV today than in the 1990s, around 13 lakh (1.3 million) people still get infected every year around the world. Lenacapavir is special because you only need two shots a year – not a pill every day like older medicines. That's great for people who forget daily pills or feel embarrassed taking them. And it's almost 100% effective at stopping HIV in adults and teens. But there's a big problem: the cost. In the US, it sells for over ₹23 lakh a year! Even rich countries find that hard to afford. The company that makes it, Gilead, is working with more than 100 poorer countries to help them make cheaper versions. Still, many African countries where HIV is most common may struggle to get it to the people who need it most. Scientists have been trying to create a proper HIV vaccine for decades, but HIV keeps mutating – changing too fast for one shot to work. New mRNA vaccines (like the ones used for Covid) are being tested, but funding cuts in the US have slowed down this research. That's why lenacapavir gives us hope. But hope only works if everyone, everywhere, can afford it. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.

Time of India

2 hours ago

• Time of India

Dose of hope

Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.

India Today

4 hours ago

• India Today

Health ministry probes AIIMS Bhopal over irregularities in medicine purchases

A team of officials from the Union Health Ministry visited AIIMS Bhopal to examine documents related to medicine procurement, following allegations by Bhopal MP Alok Sharma that the institute purchased medicines at inflated the matter was raised before the AIIMS Standing Committee on Finance during a meeting in Delhi. The central team arrived at AIIMS Bhopal on Thursday morning and examined documents related to the purchase of medicines. The team also met the Director of the institute and enquired about the purchase process. advertisement The institute has been accused of purchasing medicines directly without following the rules of the central government. In his complaint, Bhopal MP Alok Sharma mentioned that the prices of medicines purchased by AIIMS Bhopal are much more expensive than the AIIMS of other states. Sharma, who is also a member of the AIIMS standing committee, said that he had received a complaint that the injection of Gemcitabine was purchased by Bhopal AIIMS at Rs 2100 per piece, whereas it was purchased at Rs 425 by Raipur AIIMS of Chhattisgarh. Its price in Delhi AIIMS is Rs 285 per piece. The prices of other medicines were also found to be higher. "On May 15, a meeting of the AIIMS standing committee was held in New Delhi in the presence of Union health secretary Punya Salila Shrivastava. In the meeting, I complained regarding the high prices of medicines being purchased by AIIMS Bhopal. She assured me that an investigation will be conducted," said Sharma. advertisementHe also said that like other government hospitals, medicines are bought through tender in AIIMS. However, during the Covid-19 period, direct purchase of medicines was approved. "However, despite the end of the Covid-19 period, direct purchase of medicines continued and the figure of purchased medicines reached crores," he added. Must Watch